Anuh Pharma Limited has informed the Exchange regarding 'Approval from World Health Organization (WHO) Prequalification (WHO PQ) for Amodiaquine Hydrochloride USP'.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anuh Pharma Limited has received World Health Organization (WHO) Prequalification approval for Amodiaquine Hydrochloride USP, an anti-malarial Active Pharmaceutical Ingredient (API). Amodiaquine Hydrochloride is listed as an essential medicine by WHO and is widely used in combination therapies for treating uncomplicated Plasmodium falciparum malaria. The approval applies to international markets including WHO-procured and donor-funded programmes. This WHO PQ status positions the company as a preferred API supplier for global anti-malarial programmes.
This regulatory approval opens significant international market access for Anuh Pharma, particularly for WHO-procured and donor-funded anti-malarial drug programmes, which typically involve hard currency payments. The certification strengthens the company's competitive position in the global pharmaceutical API market.